- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant…
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity…
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium…
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as…
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2…
Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a…
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) -…
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional…
FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to…
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for…